INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in FS KKR Capital Corp. of Class Action Lawsuit and Upcoming Deadlines

FS KKR is facing a securities class action alleging fraud/unlawful practices, following sharp deterioration in reported fundamentals. In Q2 2025, NAV fell to $21.93 per share (-$1.44, -6.2%) and fair value of investments dropped $474M to $13.648B, with EPS at -$0.75; shares later fell 8.2% to $18.58. In Q4/full-year 2025, NAV declined further to $20.89 (-$1.10, -5%) as investment fair value fell another $406M to $13.009B; EPS was -$0.41, the dividend was cut to $0.48 from $0.70, and shares dropped 15.24% to $11.29 on the news.

Analysis

For FSK, the lawsuit is a second-order catalyst rather than the core economic problem. In BDCs, the equity usually reprices on NAV erosion, dividend durability, and non-accrual migration; litigation mainly extends the discount by keeping governance and valuation credibility under a cloud. The key mechanism is that if the loan book is still being marked too optimistically, any discovery or adverse pleadings can force a slower, uglier reset in NAV and fee-earning power than the market is currently modeling.

The likely winners are higher-quality BDCs with cleaner credit trends and better dividend coverage, especially ARCC, BXSL, and OBDC, because capital can rotate toward names where underwriting transparency supports a premium to book. The losers are levered income baskets and peers with similar middle-market exposure if FSK’s weakness is read as a read-through on the sector’s private-credit marks; BIZD is the cleanest proxy if the market starts de-risking the whole sleeve. Second-order, persistent NAV slippage at FSK can tighten financing terms across the group as lenders and repo providers reprice collateral quality.

The contrarian take is that the lawsuit itself is probably not the trade; the stock already reflects a severe credit reset and the legal process will be slow. What matters over the next 1-3 months is whether management can stabilize non-accruals and stop NAV bleed; if they do, the downside from here may be more limited than headline risk suggests. The thesis is falsified if quarterly NAV decline slows materially, dividend coverage improves, and non-accruals stop rising; conversely, another 3-5% NAV drop or a further dividend cut would likely trigger another leg down over 6-18 months.

Key Decisions for Investors

• Short FSK into any post-announcement bounce; use a 1-3 month horizon and size for event-driven decay, with the trade invalidated if the next quarter shows stable NAV and no further increase in non-accruals.
• Pair trade: long BXSL or ARCC vs short FSK for 1-3 months to isolate credit-quality dispersion; expect the cleaner names to hold premiums while FSK remains stuck at a discount if underwriting concerns persist.
• If liquidity allows, buy FSK put spreads expiring after the next earnings release to express a continued de-rating thesis with defined risk; this is best only if you expect another NAV markdown or dividend pressure.
• Watch BIZD as a sector stress proxy: if it breaks lower while FSK underperforms, fade broad BDC exposure only on confirmation of credit contagion, not on the lawsuit alone.
• Set a reversal alert on FSK if quarterly NAV stabilizes and dividend coverage returns above 100%; at that point, the market may shift from litigation overhang to mean-reversion in a beaten-down income name.